Best Read Articles on COVID-19 Drug-Related News in 2021
The attention-getting articles about COVID-19 included news about Pfizer's booster and the FDA's rejection Zyesami (aviptadil) for treatment of COVID-19-related respiratory failure.
FDA Rejects EUA for COVID-19 Respiratory Failure Therapy
The FDA didn’t have enough data to assess the risks and benefits of Zyesami.
Amber Specialty, Hy-Vee to Dispense Regeneron Monoclonal Antibody for COVID-19
Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.
Pfizer Submits EUA for COVID-19 Vaccine Booster for All Adults
The FDA had previously issued an EUA for those over the age of 65 and those at high risk for severe COVID-19 or exposure to the virus.
Concerns About Childhood COVID-19 Vaccines Persist, Despite FDA Committee OK
Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.
FDA Issues EUA for Pfizer COVID-19 Vaccine for Children
The dose is one-third of the dose given to people 12 years and older.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
